Judah Folkman
朱达·福尔克曼
MD
Julia Dyckman Andrus Professor of Pediatric Surgery (Historical); Director, Surgical Research Laboratory (Historical)朱莉娅·戴克曼·安德鲁斯小儿外科教授（历史）；外科研究实验室主任（历史）
👥Biography 个人简介
Judah Folkman (1933–2008) was the pioneering surgeon-scientist who proposed and proved the hypothesis that tumor growth beyond a few millimeters requires the induction of new blood vessel formation — a process he named angiogenesis. First published in 1971 and initially met with skepticism, his vision ultimately inspired the development of anti-angiogenic therapies including bevacizumab (Avastin), the first FDA-approved anti-angiogenic cancer drug (2004). Folkman's discovery that starving tumors of their blood supply could be a therapeutic strategy transformed understanding of the tumor microenvironment and spawned an entire class of cancer treatments now used for colorectal, lung, ovarian, and other cancers. His legacy continues through the Folkman Laboratory at Boston Children's Hospital.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Tumor Angiogenesis Hypothesis
Proposed in 1971 that solid tumor growth beyond minimal size is dependent on the induction of new blood vessels, and that blocking this process could be therapeutic — a revolutionary idea that took decades to gain acceptance.
Anti-Angiogenic Therapy Concept
Developed the conceptual and experimental basis for anti-angiogenic cancer therapy, ultimately leading to bevacizumab and over 15 FDA-approved anti-angiogenic agents.
Identification of Angiogenic Factors
Led the laboratory effort to identify and characterize tumor-derived angiogenic factors, including contributing to characterization of basic FGF and VEGF as key mediators of pathological angiogenesis.
Endostatin and Angiogenesis Inhibitors
Discovered endostatin as an endogenous angiogenesis inhibitor with anti-tumor activity, establishing the concept of endogenous anti-angiogenic regulation.
Representative Works 代表性著作
Tumor Angiogenesis: Therapeutic Implications
New England Journal of Medicine (1971)
Landmark paper proposing the angiogenesis hypothesis for solid tumor growth and first articulating anti-angiogenic therapy as a cancer treatment strategy.
Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease
Nature Medicine (1995)
Comprehensive review demonstrating the broad therapeutic relevance of angiogenesis inhibition across cancer and other diseases.
Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth
Cell (1997)
Discovery of endostatin as a potent endogenous inhibitor of angiogenesis with significant anti-tumor activity, representing a new class of cancer therapy candidate.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Faisal Mahmood
Brigham and Women's Hospital; Harvard Medical School
Kun-Hsing Yu
Harvard Medical School; Brigham and Women's Hospital
Ziad Obermeyer
University of California, Berkeley; UC San Francisco
Andrew H. Beck
PathAI; Harvard Medical School (formerly)
关注 朱达·福尔克曼 的研究动态
Follow Judah Folkman's research updates
留下邮箱，当我们发布与 Judah Folkman（Boston Children's Hospital / Harvard Medical School (Legacy)）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment